DSpace Repository

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Show simple item record

dc.contributor.author Packer, Milton
dc.contributor.author Anker, Stefan D.
dc.contributor.author Butler, Javed
dc.contributor.author Filippatos, Gerasimos
dc.contributor.author Pocock, Stuart J.
dc.contributor.author Carson, Peter
dc.contributor.author Januzzi, James L.
dc.contributor.author Verma, Subodh
dc.contributor.author Tsutsui, Hiroyuki
dc.contributor.author Brueckmann, Martina
dc.contributor.author Jamal, Waheed
dc.contributor.author Kimura, Karen
dc.contributor.author Schnee, Janet
dc.contributor.author Zeller, Cordula
dc.contributor.author Cotton, Daniel
dc.contributor.author Bocchi, Edimar
dc.contributor.author Böhm, Michael
dc.contributor.author Choi, Dong-Ju
dc.contributor.author Perrone, Sergio Víctor
dc.contributor.author EMPEROR-Reduced Trial Investigators
dc.date.accessioned 2021-04-30T14:18:35Z
dc.date.available 2021-04-30T14:18:35Z
dc.date.issued 2020-10-08
dc.identifier.citation Packer, M., Anker, S.D., Butler, J., Filippatos, G., Pocock, S.J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.-J., Chopra, V., Chuquiure, E., Giannetti, N., Janssens, S., Zhang, J., Gonzalez Juanatey, J.R., Kaul, S., Brunner-La Rocca, H.-P., Merkely, B., Nicholls, S.J., Perrone, S., Pina, I., Ponikowski, P., Sattar, N., Senni, M., Seronde, M.-F., Spinar, J., Squire, I., Taddei, S., Wanner, C., Zannad, F., 2020. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 383, 1413–1424. https://doi.org/10.1056/NEJMoa2022190 es_ES
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/447
dc.identifier.uri https://www.nejm.org/doi/10.1056/NEJMoa2022190
dc.description.abstract Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. Methods: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. Results: During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. Conclusions: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.). es_ES
dc.language.iso eng es_ES
dc.publisher Massachusetts Medical Society es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.rights.uri https://creativecommons.org/licenses/by/2.5/ar/
dc.subject Benzhydryl Compounds es_ES
dc.subject Compuestos de Bencidrilo es_ES
dc.subject Heart Failure es_ES
dc.subject Insuficiencia Cardíaca es_ES
dc.subject Renal Insufficiency, Chronic es_ES
dc.subject Insuficiencia Renal Crónica es_ES
dc.title Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Perrone, Sergio Victor. Fleni. Departamento de Neurología. Servicio de Cardiología; Argentina. Hospital de Alta Complejidad El Cruce Nestor Kirchner; Argentina.
dc.description.fil Fil: Packer, Milton. Baylor University Medical Center. Baylor Heart and Vascular Institute; Estados Unidos.
dc.relation.ispartofVOLUME 383
dc.relation.ispartofNUMBER 15
dc.relation.ispartofPAGINATION 1413-1424
dc.relation.ispartofCOUNTRY Estados Unidos
dc.relation.ispartofCITY Boston
dc.relation.ispartofTITLE The New England journal of medicine.
dc.relation.ispartofISSN 1533-4406
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Files in this item

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess

Search DSpace


Browse

My Account

Statistics